Medicine and Dentistry
Overall Survival
89%
Patient
78%
Neoplasm
70%
Hazard Ratio
70%
Stomach Cancer
70%
Capecitabine
70%
Adjuvant Chemotherapy
65%
Pancreas Adenocarcinoma
59%
Oxaliplatin
54%
Inpatient
53%
Recurrent Disease
53%
Retroperitoneal Lymph Node Dissection
47%
Uvomorulin
47%
Gemcitabine
46%
Progression Free Survival
43%
Malignant Neoplasm
42%
Fluorouracil
40%
Folinic Acid
38%
Breast Cancer
37%
Lymphocyte
37%
Palpitations
35%
Eczema
35%
Clinical Significance
35%
Liver Metastasis
35%
Retrospective Cohort Study
35%
Ampulla of Vater
35%
Lymph Node
35%
Adenocarcinoma
35%
Association
35%
Carcinomatous Peritonitis
35%
Non Small Cell Lung Cancer
35%
Breast Tumor
35%
Thyroid Gland
28%
Epidermal Growth Factor Receptor
28%
Survival
28%
Prognosis
26%
First-Line Chemotherapy
25%
Neutropenia
25%
Disease Free Survival
25%
Proportional Hazards Model
25%
Recurrence Free Survival
24%
Prognostic Factor
24%
Mortality
21%
Gastrectomy
20%
Claudin 18
20%
Neutrophil
19%
Cytotoxic T-Cell
18%
Family History
17%
Programmed Death-Ligand 1
17%
Diaphoresis
17%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Progression Free Survival
71%
Chemotherapy
56%
First-Line Chemotherapy
55%
Gemcitabine
46%
Pancreas Adenocarcinoma
41%
Neoplasm
40%
Folinic Acid
38%
Fluorouracil
38%
Irinotecan Sucrosofate
36%
Cohort Study
35%
Immune Checkpoint Inhibitor
35%
Pancreas Cancer
35%
Metastatic Breast Cancer
35%
Palbociclib
35%
Capecitabine
35%
Capecitabine
35%
Adenocarcinoma
35%
Survival
27%
Neutropenia
27%
Recurrent Disease
26%
Uvomorulin
26%
Oxaliplatin
19%
Oxaliplatin
19%
Malignant Neoplasm
18%
Prognosis
18%
Abdominal Cancer
17%
Thyroid Disease
17%
Metastatic Breast Cancer
17%
Non Small Cell Lung Cancer
17%
CA 19-9 Antigen
17%
Gemcitabine
17%
Heart Palpitation
17%
Carcinomatous Peritonitis
17%
Stomach Cancer
17%
Palbociclib
17%
Recurrent Disease
17%
CD8 Antigen
17%
Interleukin 6
17%
Recurrence Free Survival
17%
Epidermal Growth Factor Receptor
17%
Retrospective Study
15%
Thyrotoxicosis
14%
Inflammation
14%
Overall Survival
12%
Peritoneum Metastasis
12%
Guanosine Triphosphatase Activating Protein
12%
Rho Guanine Nucleotide Binding Protein
12%
Peritoneum Metastasis
12%
Guanosine Triphosphatase Activating Protein
12%
Immunology and Microbiology
Programmed Death-Ligand 1
52%
Overall Survival
41%
Progression Free Survival
27%
Lymph Node
26%
Lymphocyte
20%
Recurrence Free Survival
17%
Lymphocyte Count
17%
Ampulla of Vater
17%
CA 19-9 Antigen
17%
Neutrophil Granulocyte
17%
Association
17%
Mortality
17%
Interleukin 6
17%
Cytotoxic T-Cell
17%
Lymphopenia
12%
Cadherin
8%
MUC1
8%
Cancer Stem Cell
8%
Activating Transcription Factor
8%
Cell Marker
8%
MUC2
8%
Epithelial Mesenchymal Transition
8%
ABCG2
8%
Disease Free Survival
5%